Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis
Authors' conclusion
Trough or peak colchicine concentrations are not associated with gout flare prophylaxis efficacy. There is no consistent relationship between colchicine concentrations and colchicine-specific adverse events. Although colchicine concentrations increase with concomitant statin use, this does not result in muscle-related adverse events.
Study context
- Population
- People with gout in a 12-month RCT of low-dose colchicine vs placebo for the first 6 months while starting allopurinol; colchicine armcolchicine arm, peak and trough available
- Participants
- 79 people
- Comparison
- Relationship of colchicine plasma concentrations with clinical and demographic factors, efficacy and colchicine-specific adverse events
Primary result
As reported in the abstract
Determinants of colchicine concentrations (multivariable analysis) · month 3
- Statin use and non-Māori, non-Pacific ethnicity independently associated with higher trough concentrations
- Age >60 years independently associated with higher peak concentrations
Further findings
- Trough or peak colchicine concentrations not associated with gout flare prophylaxis efficacy
Safety
Colchicine concentrations and any adverse event between months four and six
- Trough and peak colchicine concentrations significantly higher in those with any adverse event
Colchicine concentrations and colchicine-specific adverse events (gastrointestinal and muscle) or creatine kinase (CK) changes
- No association with colchicine concentrations
Original publication
Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis. Arthritis Care Res (Hoboken). Published 23 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →